Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was the only drug approved for advanced-stage patients until the recent approvals of Stivarga (Bayer HealthCare), Opdivo (Bristol-Myers Squibb / Ono Pharmaceuticals), Keytruda (Merck & Co.), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis), and Cyramza (Eli Lilly). The late-phase development pipeline is predominantly focused on the advanced-stage HCC segment and encompasses a diverse range of mechanisms of action. Because the HCC market remains largely untapped, the developer of an efficacious therapy could reap high commercial rewards.

Questions Answered

  • What is the current treatment landscape for HCC, and what clinical needs remain unfulfilled?
  • Which drug classes are in the late-phase development pipeline, and which agents are the most promising?
  • What are the clinically and commercially relevant drug-treatable patient populations in HCC, and how will drug-treatment rates change (if at all) over time?
  • Which emerging therapies do we forecast to enter each of the HCC market segments? What uptake and sales are these therapies anticipated to secure?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 22 country-specific interviews with thought leaders (medical oncologists and hepatologists).

Key companies: Bayer HealthCare/Amgen/Onyx , Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co., Eisai, Exelixis/Ipsen.

Key drugs: Nexavar, Stivarga, Opdivo, Lenvima, Keytruda, Cabometyx, Cyramza.

Population segments in market forecast: Early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.

Emerging therapies: Phase III: approximately 7 drugs; Phase II: approximately 15 drugs; coverage of select Phase I and preclinical products.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
    • Key Updates
      • December 2019
      • July 2019
      • May 2019
      • December 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Hepatocellular Carcinoma?
        • What Factors Are Constraining the Market for Hepatocellular Carcinoma?
      • Segment-Specific Trends
        • Early-Stage Hepatocellular Carcinoma
        • Intermediate-Stage Hepatocellular Carcinoma
        • First-Line Advanced-Stage Hepatocellular Carcinoma
        • Second-Line Advanced-Stage Hepatocellular Carcinoma
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions - Hepatocellular Carcinoma (2018-2028) - December 2019
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Disease Pathophysiology
      • Staging and Classification
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Hepatocellular Carcinoma
        • Recurrent Incident Cases of Hepatocellular Carcinoma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Angiogenesis Inhibitors
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • ​Early-Stage Hepatocellular Carcinoma
        • Intermediate-Stage Hepatocellular Carcinoma
        • Advanced-Stage Hepatocellular Carcinoma
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Hepatocellular Carcinoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • Oncolytic Viral Therapies
        • Retinoid Nuclear Receptor Agonists
        • Cytotoxic Agents
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Hepatocellular Carcinoma
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Hepatocellular Carcinoma Bibliography

Author(s): Neela Rambaruth; Oliver Blandy

Neela Rambaruth is a Business Insights Analyst in the Oncology division at DRG. Neela joined DRG in 2018 and has since authored the Disease Landscape and Forecast report for non-small-cell lung cancer. Neela is currently working on the Disease Landscape and Forecast report for Hepatocellular carcinoma and the survey for Immune checkpoint US Access and Reimbursement. Prior to joining DRG, Neela Rambaruth was a Postdoctoral Scientist at University College London, where she investigated the interaction of novel drugs with a therapeutic receptor involved in cardiovascular ; She also held another postdoctoral position at Imperial College London, where she studied host-pathogen interaction in tuberculosis. Dr Rambaruth holds a PhD in Breast Oncology from the University of ; Her doctorate focused on the identification of novel biomarkers associated with metastatic breast cancer. She has also published several peer-reviewed articles in oncology and therapeutic drug discovery.

Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer. Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years. Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.

Related Reports

Hepatocellular Carcinoma | Geographic Focus: China | Hepatocellular Carcinoma | China In-Depth | China

MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience a sudden explosion in market growth. Availability of existing systemic agents...

View Details